G S Cooper1, Z Yuan, A Chak, A A Rimm. 1. Department of Epidemiology and Biostatistics, Case Western Reserve University, University Hospitals of Cleveland, Ohio 44106, USA.
Abstract
BACKGROUND: There are a paucity of data supporting the routine use of follow-up testing to detect recurrent disease after potentially curative initial surgery in patients with nonmetastatic colorectal carcinoma. METHODS: Using the population-based Surveillance, Epidemiology, and End Results (SEER) registry, all patients age > or =65 years with local or regional colorectal carcinoma who were diagnosed in 1991, underwent surgical resection, and survived at least 6 months after diagnosis were identified. All inpatient, hospital outpatient, and physician/supplier Medicare claims from 6 months after diagnosis through 1994 were examined for follow-up procedures of interest. Procedure use during follow-up was compared across patient groups using both bivariate and multivariate analyses. RESULTS: A total of 5716 patients were identified, with 1.3% found to have developed subsequent primary tumors of the colon or rectum, and 74% surviving through 1994. One or more procedures of interest were performed in 88% of patients; the most commonly performed tests were liver enzymes, chest X-rays, colonoscopy, and computed tomography scans. Lower rates of testing generally were observed with older age groups, patients with fewer comorbidities, and patients who did not survive through the follow-up period. Among all procedures studied, there also was significant variation in the rates of testing across the 9 SEER areas, varying from 1.5-fold to 3.6-fold. The geographic variation persisted in multivariate models adjusting for potentially confounding factors. CONCLUSIONS: The current study found significant variability in the use of follow-up procedures, with the most striking differences apparent across geographic regions. Further studies are needed to determine the underlying reasons for the disparities, as well as the impact of surveillance on patient outcomes.
BACKGROUND: There are a paucity of data supporting the routine use of follow-up testing to detect recurrent disease after potentially curative initial surgery in patients with nonmetastatic colorectal carcinoma. METHODS: Using the population-based Surveillance, Epidemiology, and End Results (SEER) registry, all patients age > or =65 years with local or regional colorectal carcinoma who were diagnosed in 1991, underwent surgical resection, and survived at least 6 months after diagnosis were identified. All inpatient, hospital outpatient, and physician/supplier Medicare claims from 6 months after diagnosis through 1994 were examined for follow-up procedures of interest. Procedure use during follow-up was compared across patient groups using both bivariate and multivariate analyses. RESULTS: A total of 5716 patients were identified, with 1.3% found to have developed subsequent primary tumors of the colon or rectum, and 74% surviving through 1994. One or more procedures of interest were performed in 88% of patients; the most commonly performed tests were liver enzymes, chest X-rays, colonoscopy, and computed tomography scans. Lower rates of testing generally were observed with older age groups, patients with fewer comorbidities, and patients who did not survive through the follow-up period. Among all procedures studied, there also was significant variation in the rates of testing across the 9 SEER areas, varying from 1.5-fold to 3.6-fold. The geographic variation persisted in multivariate models adjusting for potentially confounding factors. CONCLUSIONS: The current study found significant variability in the use of follow-up procedures, with the most striking differences apparent across geographic regions. Further studies are needed to determine the underlying reasons for the disparities, as well as the impact of surveillance on patient outcomes.
Authors: Daisy Le; Cheryl L Holt; Maria Pisu; Aquila Brown-Galvan; Temeika L Fairley; Judith Lee Smith; Arica White; Ingrid J Hall; Robert A Oster; Michelle Y Martin Journal: J Psychosoc Oncol Date: 2014
Authors: L N van Steenbergen; I H J T de Hingh; H J T Rutten; M C M Rijk; R G Orsini; J W W Coebergh; V E P P Lemmens Journal: Int J Colorectal Dis Date: 2013-04-28 Impact factor: 2.571
Authors: Talya Salz; Morris Weinberger; John Z Ayanian; Noel T Brewer; Craig C Earle; Jennifer Elston Lafata; Deborah A Fisher; Bryan J Weiner; Robert S Sandler Journal: BMC Health Serv Res Date: 2010-09-01 Impact factor: 2.655
Authors: Melissa Y Carpentier; Sally W Vernon; L Kay Bartholomew; Caitlin C Murphy; Shirley M Bluethmann Journal: J Cancer Surviv Date: 2013-05-16 Impact factor: 4.442
Authors: Talya Salz; Noel T Brewer; Robert S Sandler; Bryan J Weiner; Christopher F Martin; Morris Weinberger Journal: J Cancer Surviv Date: 2009-09-16 Impact factor: 4.442
Authors: Jensen Tan; Jennifer Muir; Natalie Coburn; Simron Singh; David Hodgson; Refik Saskin; Alex Kiss; Lawrence Paszat; Abraham El-Sedfy; Eva Grunfeld; Craig Earle; Calvin Law Journal: Can J Gastroenterol Hepatol Date: 2014-07-11